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Abstract
The ability to reliably evaluate the impact of interventions and changes in hypertension prevalence 
and control is critical if the burden of hypertension-related disease is to be reduced. Previously, a 
World Hypertension League Expert Committee made recommendations to standardize the 
reporting of population blood pressure surveys. We have added to those recommendations and also 
provide modified recommendations from a Pan American Health Organization expert meeting for 
“performance indicators” to be used to evaluate clinical practices. Core indicators for population 
surveys are recommended to include: (1) mean systolic blood pressure and (2) mean diastolic 
blood pressure, and the prevalences of: (3) hypertension, (4) awareness of hypertension, (5) drug-
treated hypertension, and (6) drug-treated and controlled hypertension. Core indicators for clinical 
registries are recommended to include: (1) the prevalence of diagnosed hypertension and (2) the 
ratio of diagnosed hypertension to that expected by population surveys, and the prevalences of: (3) 
controlled hypertension, (4) lack of blood pressure measurement within a year in people diagnosed 
with hypertension, and (5) missed visits by people with hypertension. Definitions and additional 
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indicators are provided. Widespread adoption of standardized population and clinical hypertension 
performance indicators could represent a major step forward in the effort to control hypertension.
1 Background
Increased blood pressure (BP) is the leading risk factor for death and disability globally.1,2 
Hence, in the context of the noncommunicable disease global monitoring framework,3 a 
specific target was established by the World Health Organization (WHO) to reduce by 25% 
the prevalence of raised BP (defined as a BP of ≥140/90 mm Hg) by 2025.2 That critical 
target, reducing raised BP or “uncontrolled hypertension,” provides a priority call to action 
to national governments and hypertension-related health and scientific organizations. 
However, to measure progress towards the achievement of the targets, a key issue is the 
identification of further performance indicators that are needed to help guide hypertension 
control efforts at a population and a healthcare organization level.4,5
This paper discusses a set of standardized performance indicators that could be used for 
continuous quality improvement, to help prioritize the most cost-effective of interventions, 
and for good governance in the effort to reduce the burden of hypertension-related disease. 
Performance indicators are provided for both clinical hypertension control interventions and 
for population BP control programs. The World Hypertension League's (WHL's) mission is 
devoted to hypertension prevention and control in the population.6 The paper is based on 
WHL guidance for analyzing hypertension surveys as well as a Pan American Health 
Organization (PAHO) meeting on hypertension metrics, and experiences in optimizing BP 
control from communities and clinic-based programs.7–9 We hope this manuscript will 
stimulate others to implement standardized performance indicators into hypertension 
programs as a critical component of the effort to successfully control hypertension.
2 Indicators For Hypertension Control at a Population Level
The WHL expert Committee recommended a set of “core” (Table 1) as well as “expanded” 
and “optional” indicators to be used in population BP surveys.9 The indicators were made in 
part to standardize approaches to developing and analyzing hypertension surveys, thus 
facilitating comparison between surveys. The standardization is essential for population 
hypertension control programs to evaluate their progress towards the global target, to reduce 
uncontrolled hypertension, to identify best practices that can be shared between 
hypertension control programs, and to provide a global basis for comparison. A primary data 
source for population BP is the STEPwise approach to Surveillance (STEPS) from the 
WHO, which is designed to assess chronic disease risk factors including BP.10
2.1 Core indicators
The prevalence of hypertension and the distribution of BP across the population are the 
major indicators necessary to assess the effectiveness of policies and interventions to prevent 
and treat hypertension. Health system and community-level interventions that reduce 
population BP will also have a significant impact on hypertension treatment and control 
rates by reducing the BP of patents with hypertension, even in individuals who may not be 
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aware or treated.11 For example, in Canada, it was estimated that reducing dietary salt 
towards recommended targets would reduce the prevalence of hypertension by 30% and also 
double the rate of hypertension control with no change in drug treatment.11 The WHL expert 
committee recommended that prevalence be assessed by two methods (Table 1). The usual 
definition used in national surveys is to define hypertension as people with blood pressure 
≥140 mm Hg systolic or 90 mm Hg diastolic or taking medications to treat hypertension. A 
second more inclusive definition, prevalence of awareness of hypertension, uses the same 
criteria as the first method but also includes patents diagnosed with hypertension by a 
healthcare professional.
Hypertension “awareness,” treatment, and control rates were recommended to assess the 
impact of efforts to reduce uncontrolled BP in populations (see Table 1). Hypertension 
awareness assesses the effectiveness of healthcare organizations and community programs to 
diagnose hypertension. Hypertension treatment and control rates assess primarily, the 
effectiveness of the healthcare system to provide antihypertensive drugs to people with 
hypertension and to control hypertension respectively, and the effectiveness of population 
health interventions (eg, dietary salt reduction policies).
2.2 Expanded and optional indicators
Expanded indicators are optional and may not be feasible in all settings. The WHL expert 
committee recommended the “core” hypertension indicators to be evaluated in patients with 
isolated systolic hypertension and patients with both hypertension and diabetes. Other 
recommended expanded indicators were antihypertensive drug treatment among persons 
aware of having hypertension, control among antihypertensive drug-treated patients, 
adherence to lifestyle recommendations, and the proportion of the population with 
prehypertension. It was recommended to assess relevant ethnic and sociodemographic 
characteristics in analyses of the core and expanded indicators. The specific definitions of 
these indicators are provided in the original publication, which also provides 
recommendations for a variety of optional indicators as well as recommendations for 
research on hypertension indicators.9
In addition to the suggested analyses in the WHL report, we propose performance indicators 
to specifically address “clinical care gaps.” These care gaps include the proportions of 
patients defined as having hypertension using the usual definition that are: (1) undiagnosed, 
(2) not treated with antihypertensive drugs (“untreated”), and (3) treated with 
antihypertensive drugs but not controlled (“uncontrolled”). Although these “care gap” 
indicators are the inverse of the previously suggested core indictors, the care gap indicators 
can be examined by major sociodemographic characteristics (eg, age, sex, ethnicity, and 
socioeconomic status) to facilitate developing interventions to reduce the care gap. An 
example of the utility of examining care gaps occurred in the Canadian Hypertension 
Education Program where analysis revealed that most persons with undiagnosed 
hypertension were young men who were unlikely to be accessing the healthcare system.12 
This fact suggested that efforts to reduce undiagnosed hypertension through increased 
assessment of BP within the traditional healthcare system would not be likely to be effective 
at targeting this specific population, but that programs such as assessing BP outside the 
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traditional healthcare delivery model (eg, in the workplace) would be more likely to be 
effective.
3 Performance Indicators For Hypertension Control at Healthcare 
Organizations
PAHO hosted a workshop in December 2015 to start discussions to identify specific 
performance indicators that could be used for monitoring hypertension management at the 
healthcare facility level. The discussions were informed by the experience in developing 
performance indicators to facilitate controlling BP among individuals in the Kaiser 
Permanente Northern California healthcare delivery system.8 Several other groups have also 
advocated for performance indicators to assess hypertension control efforts at the healthcare 
organization level.13-17 Table 2 provides modified recommendations from the PAHO 
workshop, and Table 3 indicates the data that are required to be collected for the core 
performance indicators. Assessing performance indicators requires the clinic as well as the 
healthcare organization to have a registry of persons diagnosed with hypertension that 
documents the patent data pertinent to the performance indicators. Clinical performance 
indicators are selected to assess progress towards specific goals to enhance the quality of 
care in the specific clinical population that is being served and hence may be different than 
population indicators.
Core analysis performed in healthcare organizations is suggested to include the prevalence 
of hypertension in the clinic registry. The registry prevalence should be compared as a ratio 
to the expected prevalence in the population as an indirect assessment of the number of 
people with undiagnosed hypertension in the clinical population (ie, if the registry 
prevalence of hypertension is lower than the expected prevalence based on population 
surveys, the difference may reflect undiagnosed hypertension). The prevalence of controlled 
hypertension assesses the key performance indicator for reducing the burden of hypertension 
clinically and we have recommended a simplified performance indicator (BP <140 mm Hg 
systolic and 90 mm Hg diastolic for those registered as having hypertension). A wide variety 
of expanded performance indicators may assist clinics in assessing hypertension control in 
vulnerable or high-risk populations and in guiding treatment for those most likely to 
experience the greatest benefit (Table 2).
4 Discussion
This commentary from the WHL, PAHO, the US Centers for Disease Control and 
Prevention (CDC), and other partners is intended to promote discussion around a 
standardized approach to hypertension indicators to augment the single WHO indicator of a 
25% relative reduction in the prevalence of raised BP and to facilitate planning of 
interventions to improve prevention and control of hypertension. We have advocated 
expansion of the previous WHL expert committee recommendations9 to include 
performance indicators assessing clinical care gaps at a population as well as a healthcare 
organization level. The performance indicators are intended to facilitate prioritization of 
interventions to populations and communities where significant opportunities for care 
improvement exist and may provide useful information to enable policy change or system 
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implementation designed to reduce the burden of hypertension-related disease. We note that 
the definition of “uncontrolled hypertension” or “raised blood pressure” is largely based on 
the efficacy of drug therapy to reduce cardiovascular events and is subject to change based 
on emerging research. For example, hypertension was previously defined as a systolic BP 
>160 mm Hg before research demonstrated the efficacy of antihypertensive drug treatment 
to reduce cardiovascular disease at lower BP levels.18
In addition, the commentary is intended to promote discussion on clinical hypertension 
performance indicators. The development and implementation of performance indicators for 
clinical practice are envisioned to be integrated into efforts to systematically improve the 
quality and consistency of hypertension care, and, eventually, to improve the quality of care 
of other prevalent chronic conditions. The performance indicators can also be used to track 
clinical interventions that are most cost-effective, for example by developing metrics to track 
the use of specific medications that have been identified as being effective, affordable, and 
well tolerated. Assessing performance indicators in clinical practice is only feasible with a 
hypertension registry that is preferably linked to an electronic medical record. However, the 
use of an electronic health record in a population is not an indispensable requirement for the 
creation of a useful hypertension registry. For example, the Kaiser Permanente Northern 
California hypertension program began by using a paper registry for 6 years before 
transitioning to electronic registry data capture.6 In other words, electronic medical records 
are not a prerequisite even though they are desirable and the availability of an electronic 
medical record is not a “rate limiting step” to starting a program.
The participants in the PAHO workshop recommended that both systolic and diastolic BP be 
used in the registry; however, if greater simplicity was necessary, then only systolic BP 
could be used and would likely identify the majority of people with hypertension. It was 
recognized that the fewer and more important “core” performance indicators that were 
selected, the more likely clinicians were to enter data into the registry. Nevertheless, it was 
understood that the performance indicators could be tailored to each unique clinical 
environment; hence, a menu of “optional” performance indicators is provided to help guide 
the selection of performance indicators of greatest practice importance. Optional indicators 
included the frequency of use of “recommended” drugs. Within the PAHO-CDC 
hypertension initative,19 recommended drugs are included under PAHO's Strategic Fund, 
which provides high-quality medication at very competitive prices.20 Within the Kaiser 
Permanente program, “recommended” drugs are included in a standardized care algorithm 
designed to improve hypertension control. Another optional analysis is based on examining 
hypertension control in people with a calculated cardiovascular risk at 10 years of over 20%. 
Clinics may wish to select this performance indicator to include patents with a calculated 
risk at a lower level (eg, >10% risk at 10 years) to identify those with hypertension where 
therapy is cost-effective in their resource setting. Although using cardiovascular risk as an 
indicator was indicated to require more research to be integrated into population surveys, the 
PAHO expert meeting recommended its consideration as a clinical performance indicator. 
Most people with hypertension in clinics are at much higher risk than the general population 
and the cost-effectiveness of drug treatment is highly dependent on baseline cardiovascular 
risk.
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Performance indicators should be regularly evaluated at the healthcare organization level to 
assess progress in improving BP control rates and to identify care gaps where changes to 
ongoing interventions may be required. When common performance indicators are used they 
can also be used to compare different practice settings and share best practices. The 
experience of the authors suggests initiating hypertension registries with very few 
performance indicators (eg, prevalence, diagnosis, treatment and control, missed 
appointments, and lack of BP readings in the preceding year) to simplify program 
implementation and analysis of the performance indicators. Once the clinical team becomes 
comfortable with reviewing and assessing these indictors, an expanded set may be 
incorporated.
In general, each selected hypertension performance indicator at the population or healthcare 
organization level should have an associated target and a timeline for the target to be 
achieved. As part of continuous quality improvement processes, serial evaluation can assess 
progress towards the target and be used to identify interventions that need to be adjusted and 
modified. For many metrics, a target of 100% is both unachievable and clinically 
inappropriate, and perhaps even counterproductive, as interventions need to be tailored to the 
unique characteristics of each patent. For example, in individuals with white-coat 
hypertension, controlling clinic BP is not recommended. Performance metrics based on BP 
control for specific subgroups based on hypertension stage and global cardiovascular risk 
would facilitate prioritization of treatment strategies especially in low-resource 
environments.1,9
5 Conclusions
As the global population ages, hypertension management will remain a major health issue 
globally and clinical performance measurements a critical component to understand the 
global burden and to assess the impact of interventions. These metrics need to be further 
enhanced with input from all regions of the world.
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Table 1
Summary of definitions for recommended core performance indicators at a population 
level in population-based surveysa
Performance indicator Numerator Denominator
Core performance indicators
 Mean systolic blood pressure Sum of valid average systolic blood pressure in the blood pressure 
surveya
Total number of respondents 
aged 18-69 y who had a valid 
blood pressure reading
 Mean diastolic blood pressure Sum of valid average diastolic blood pressure in the blood 
pressure surveya
Total number of respondents 
aged 18-69 y who had a valid 
blood pressure reading
 Prevalence of hypertension Respondents who have systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg or who report currently 
taking medication for the treatment of high blood pressure 
(definition A)
Respondents who have systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg or who report currently 
taking medication for the treatment of high blood pressure or who 
report having been diagnosed with hypertension by a health 
professional (definition B)
Respondents aged 18-69 y
 Prevalence of awareness of 
hypertension
Respondents who report either having been diagnosed with high 
blood pressure or who report being currently treated with 
medication for high blood pressure
Respondents with 
hypertension according to 
definition A
 Prevalence of treatment of 
hypertension
Respondents who report being currently treated with medication 
for high blood pressure
Respondents with 
hypertension according to 
definition A
 Prevalence of drug-treated and 
controlled hypertension
Respondents who report being currently treated with medication 
for high blood pressure and have systolic blood pressure <140 mm 
Hg and diastolic blood pressure <90 mm Hg
Respondents with 
hypertension according to 
definition A
 Prevalence of controlled 
hypertension
Respondents who report being currently treated with medication 
for high blood pressure or have been diagnosed with hypertension 
and have systolic blood pressure <140 mm Hg and diastolic blood 
pressure <90 mm Hg
Respondents with 
hypertension according to 
definition B
Reproduced from reference.9 Standard deviations of mean systolic and diastolic blood pressure and 95% confidence intervals for the proportions 
should be calculated. Each of these core performance indicators can be reported overall and by age group (18-29, 30-49, and 50-69 years) and sex, 
with crude and age-standardized (to the World Health Organization World standard) changes tracked over time.
Reporting core indicators among people with diabetes, those with isolated systolic hypertension, and among sociodemographic groups is 
recommended as expanded analyses.
a
In the STEPwise approach to Surveillance system, average systolic and diastolic blood pressure are calculated from two of three blood pressure 
readings, taken 3 minutes apart, with preference given to the last two measurements.10
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Table 2
Performance indicators for use in clinics and at the healthcare organizations
Performance indicator Numerator Denominator
Core performance indicators
 Prevalence of diagnosed hypertension Patents who have systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg or who report 
currently taking medication for the treatment of high 
blood pressure
Adult patents in the adult clinic 
population
 Ratio of prevalence of diagnosed 
hypertension to the expected prevalence of 
hypertension
Prevalence of diagnosed hypertension Expected age-adjusted prevalence of 
hypertension in the populationa
 Cardiovascular risk assessment Registrants with a recorded cardiovascular risk 
assessment within 5 y
Registrants with hypertension
 High calculated cardiovascular riskb Registrants with calculated cardiovascular disease risk ≥20% in 10 y, systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg, and taking 
antihypertensive medication
Registrants with hypertension
 High calculated cardiovascular riskb Registrants with calculated cardiovascular disease risk ≥20% in 10 y, systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg, and not taking 
antihypertensive medication
Registrants with hypertension
 Prevalence of controlled hypertension Respondents who report being currently treated with 
medication for high blood pressure and have systolic 
blood pressure <140 mm Hg and diastolic blood pressure 
<90 mm Hg
Registrants with hypertension aged 
18-69 y
 Lack of opportunity No recorded blood pressure in the past year Registrants with hypertension
 Missed visits Registrants who have missed a hypertension-related 
appointment
Registrants with hypertension
Optional performance indicators
 Uncontrolled hypertension 1 Registrants with systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg and cardiovascular 
disease, renal disease, or diabetes mellitus
Registrants with hypertension
 Uncontrolled hypertension 2 Registrants with systolic blood pressure ≥160 mm Hg or 
diastolic blood pressure ≥100 mm Hg and not taking 
antihypertensive medication
Registrants with hypertension
 Uncontrolled hypertension 3 Registrants with systolic blood pressure ≥160 mm Hg or 
diastolic blood pressure ≥100 mm Hg taking 
antihypertensive medication
Registrants with hypertension
 Use of recommended antihypertensive 
drugsc
Registrants prescribed “core-recommended” 
antihypertensive drugs
Registrants with hypertension
 “Resistant” hypertensiond Registrants with blood pressure ≥160/100 mm Hg treated 
with three or more antihypertensive drugs
Adult patents with hypertension
 Appropriate treatment of black patents Registrants who are black and being treated with 
medications that do not include either a diuretic or 
calcium channel-blocking antihypertensive medication
Registrants with hypertension who 
are black
a
The observed prevalence of hypertension will need to be restricted to the same age range as the population survey for this indicator as 
hypertension prevalence rises with age.
b
The performance indicator is the use of a validated cardiovascular risk assessment tool with the registrant's risk recorded.
c
This performance indicator requires that the clinic has established a core set of medications. The core medications are selected to facilitate a 
standard approach to hypertension treatment with cost-effective and appropriate antihypertensive drugs.
d
This definition of resistant hypertension is modified for a primary care low-resource setting.
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Table 3
Recommended data to be obtained for the core performance indicators for use at the 
healthcare organizations
Age (date of birth)
Sex
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Antihypertensive medication use (yes, no)
Blood pressure recorded in the past year (yes, no)
Missed last follow-up appointment (yes, no)
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